Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE$_2$ in primary rat microglia

Johannes CM Schlachetzki$^{1,2}$, Bernd L Fiebich$^{1,*}$, Elisabeth Haake$^1$, Antonio CP de Oliveira$^3$, Eduardo Candelario-Jalil$^3$, Michael T Heneka$^4$, Michael Hüll$^1$

Abstract

Background: Recent studies suggest an important role for neurotransmitters as modulators of inflammation. Neuroinflammatory mediators such as cytokines and molecules of the arachidonic acid pathway are generated and released by microglia. The monoamine norepinephrine reduces the production of cytokines by activated microglia \textit{in vitro}. However, little is known about the effects of norepinephrine on prostanoid synthesis. In the present study, we investigate the role of norepinephrine on cyclooxygenase-2 (COX-2) expression/synthesis and prostaglandin (PG) E$_2$ production in rat primary microglia.

Results: Interestingly, norepinephrine increased COX-2 mRNA, but not protein expression. Norepinephrine strongly enhanced COX-2 expression and PGE$_2$ production induced by lipopolysaccharide (LPS). This effect is likely to be mediated by $\beta$-adrenoreceptors, since $\beta$-, but not $\alpha$-adrenoreceptor agonists produced similar results. Furthermore, $\beta$-adrenoreceptor antagonists blocked the enhancement of COX-2 levels induced by norepinephrine and $\beta$-adrenoreceptor agonists.

Conclusions: Considering that PGE$_2$ displays different roles in neuroinflammatory and neurodegenerative disorders, norepinephrine may play an important function in the modulation of these processes in pathophysiological conditions.

Background

Microglia, the innate immune cells of the brain, constantly screen their microenvironment and transform into an “activated” state in response to brain lesions, e.g., toxic lesions or debris and degenerating neurons [1,2] (for review see [3]). Once activated, microglia secrete pro- and anti-inflammatory mediators such as cytokines and prostaglandins (for review see [4]). \textit{In vitro} stimulation with lipopolysaccharide (LPS), the endotoxin of gram-negative bacteria, results in the secretion of neurotoxic and pro-inflammatory mediators. LPS triggers the activation of microglial cells via the anchored surface myeloid glycoprotein CD14 [5]. CD14 has also been found to bind to amyloid-$\beta$ (A$\beta$), the major compound found in amyloid plaques in the brains of patients with Alzheimer’s disease (AD) [6].

LPS is known to induce the production of cyclooxygenase-2 (COX-2) enzyme in microglial cells \textit{in vitro} [7-9]. COX-2 converts arachidonic acid released from membrane phospholipids to prostaglandin (PG) H$_2$. PGH$_2$ is then isomerized to PGE$_2$ by terminal prostaglandin E synthases. COX-2 has emerged as a major player in inflammatory reactions in the brain and increased COX-2 expression has been considered to contribute to neurodegeneration [10,11]. Elevated COX-2 expression has been described in AD [12-17] and COX-2 protein content in the hippocampus of AD patients may correlate with the severity of dementia [18]. On the other hand, COX-2 has been suggested to play a physiological role in the brain for being involved in neuronal plasticity and synaptic transmission [19,20].

In recent years it has become evident that there may exist a crosstalk between the autonomic nervous system

$^*$ Correspondence: bernd.fiebich@uniklinik-freiburg.de; michael.huell@uniklinik-freiburg.de
$^\dagger$ Contributed equally
$^1$ Department of Psychiatry and Psychotherapy, University Hospital of Freiburg, Freiburg, Germany

© 2010 Schlachetzki et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
and the immune system during inflammation [21,22]. The catecholamine norepinephrine (NE) is a classical neurotransmitter with suggested immunomodulatory properties. NE is released by neurons into the synaptic cleft and may exert effects on glial cells that are in close vicinity. NE binds to α- and β-adrenergic receptors, and expression of α₁, α₂, β₁, and β₂-adrenergic receptors have been identified on microglia [23-29].

An immunosuppressive role has been suggested for NE in vitro since it attenuates LPS-induced microglial production of tumour necrosis factor (TNF)α, interleukin (IL)-1β, IL-6 and nitric oxide in vitro [24,30,31]. NE has been shown to reduce microglia-induced neuronal cell death [30,32].

Although it is known that NE has immunosuppressive properties, information of NE’s effect on prostaglandins is scarce. The aim of our study was to further investigate the role of NE on eicosanoid production, namely PGE₂ in primary rat microglia.

Methods

Chemicals and reagents
L-(-)-Norepinephrine (+) bitartrate salt monohydrate (A9512), LPS, the α₁-adrenergic agonist L-phenylephrine hydrochloride and the β₂-adrenergic agonist terbutaline hemisulfate salt were obtained from Sigma-Aldrich (Taufkirchen, Germany). ICI 118,551, a selective β₂-antagonist, and CGP 20712A, a selective β₁-antagonist, the α₂-receptor agonist clonidine, the α₁-receptor antagonist nicergoline, and the β₁/β₂-receptor agonist dobutamine were obtained from Tocris (distributed by Biotrend, Cologne, Germany).

Cell culture
Primary microglial cell cultures were established from cerebral cortices of one-day-old neonatal Wistar rats as previously described [7,33]. Briefly, forebrains were minced and gently dissociated by repeated pipetting in Hank’s balanced salt solution. Cells were collected by centrifugation, resuspended in Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum and antibiotics and cultured on 10-cm cell culture dishes (Falcon, 5 × 10⁵ cells/plate) in 5% CO₂ at 37°C. Medium was prepared taking extreme care to avoid LPS contamination [34]. Floating microglia were harvested from 10- to 14-day-old mixed (astrocyte-microglia) primary cultures and re-seeded into 35-mm cell culture dishes in fresh complete medium to give pure microglial cultures (2 × 10⁴ cells/dish). Microglial cultures were washed 1 h after seeding to remove non-adherent cells. The purity of the microglial culture was >98% as previously determined by immunofluorescence and cytochemical analysis [34].

RNA extraction and RT-PCR analysis
Total RNA was isolated using the guanidine isothiocyanate method [35]. Two μg of total RNA was reverse transcribed using M-MLV reverse transcriptase and random hexamers (Promega, Mannheim, Germany). One μl of the resulting cDNA was amplified using Taq DNA polymerase (Promega), dNTPs (Invitreek, Berlin, Germany) and primers specific for rat COX-1 (forward, 5'-CGG CCT CGA CCA CTA CCA ATG-3'; reverse, 5'-TGC GGG GCG GGA ATG AAC T-3', annealing temperature 60°C, 30 cycles, amplicon size: 426 bp); rat COX-2 (forward: 5’ TGC GAT GCT CTT CCG AGC TGT GCT 3’, reverse: 5’ TCA GGA AGT TCC TTA TTT CCT TTC 3’, annealing temperature 55°C, 35 cycles, amplicon size: 479 bp); rat S12 (forward: 5’-AGC TCA ACA CTG CTC TAC A-3’, reverse: 5’-CTT TGC CAT AGT CCT TAA C-3’, 56°C, 30 cycles, amplicon size: 312 bp), that were designed using Primer Select software (DNA Star Inc., Madison, WI) and synthesized through an in-house facility (Dr. Gabor Igloi, Institute for Biology III, Freiburg, Germany). All PCR amplifications included a final 10-min extension at 72°C. The products were analyzed on a 2% agarose gel. Contamination by genomic DNA was identified by substituting total RNA instead of cDNA in the reaction mixture using S12 primers.

Western blot analysis
After the respective experimental set up, microglial cells were washed with phosphate-buffered saline (PBS) and lysed in 1.3 × SDS- (sodium dodecyl sulfate-) containing sample buffer without DTT or bromophenol blue containing 100 μM orthovanadate [36]. Lysates were homogenized by repeated passage through a 26-gauge needle. Protein contents were measured using the bicinchoninic acid (BCA) method (kit obtained from Pierce, distributed by KFC Chemikalien, München, Germany). Bovine serum albumin (BSA) was used as a protein standard at concentrations ranging from 0.2 μg/μl to 4 μg/μl; the optical density was read at 570 nm using a microplate reader. Before electrophoresis, bromophenol blue and DTT (final concentration, 10 mM) were added to the samples. For COX-1 and COX-2 immunoblotting, 30 to 50 μg of protein from each sample was subjected to SDS-PAGE (polyacrylamide gel electrophoresis) on a 10% gel under reducing conditions. Proteins were then transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA, USA) by semi-dry blotting. The membrane was blocked for 1 or 2 h at room temperature using Rotiblock (Roth, Karlsruhe, Germany) or 5% blocking milk (BioRad, München, Germany), before the overnight incubation at 4°C with the primary antibody. Primary antibodies were goat anti-COX-1 goat (M-20, Santa Cruz, Heidelberg, Germany) and anti-COX-2 diluted 1:500 in Tris-buffered saline (TBS) containing 0.1% Tween 20 (Merck, Darmstadt, Germany) and 1% bovine serum albumin (BSA) and rabbit anti-actin diluted 1:5000 (Sigma, St. Louis, MO, USA). After
extensive washing (three times for 15 min each in TBS containing 0.1% Tween 20), proteins were detected with horseradish peroxidase (HRP)-coupled rabbit anti-goat IgG (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, 1:100,000) or HRP-coupled donkey anti-rabbit (GE Healthcare, Freiburg Germany, 1:25,000) using chemiluminescence (ECL) reagents (GE Healthcare). All western blot experiments were carried out at least three times.

**Enzyme immunoassay (EIA)**

Supernatants were harvested, centrifuged at 10,000 × g for 10 min, and levels of prostaglandin E2 in the media were measured by enzyme immunoassay (EIA) (Assay design, distributed by Biotrend, Cologne, Germany and Cayman Chemicals, Ann Arbor, MI, USA, respectively) according to the manufacturer’s instructions. Standards from 39 to 2500 pg/ml were used; sensitivity of the assay was 36.2 pg/ml.

**Statistical analysis**

At least three independent experiments were used for data analysis. Original data were converted into %-values of LPS control and mean ± S.E.M. were calculated. Values were compared using t-test (two groups) or one-way ANOVA with post-hoc Student-Newman-Keuls test (multiple comparisons). Differences were considered statistically significant when p < 0.05.

**Results**

**NE enhances LPS-induced production of COX-2 mRNA and protein in primary rat microglial cells**

We show here that NE dose-dependently enhanced LPS-induced COX-2 protein levels in primary rat microglia (Fig. 1A). No COX-2 protein levels were detected after 4 h stimulation with LPS (10 ng/ml) alone. Moreover, NE alone showed no effect. Addition of 1-100 nM NE to LPS-stimulated cells did not increase COX-2 protein levels, although 100 nM NE in combination with LPS already showed a tendency to increase COX-2 levels. Significant upregulation of COX-2 immunoreactivity was observed at doses of 1 to 10 μM NE in combination with LPS. Analysis of western blots from three independent experiments showed a 22- and 35-fold increase in COX-2 immunoreactivity in rat primary microglial cells (p < 0.001) using 1 and 10 μM NE, respectively, as compared to 10 ng/ml LPS alone (Fig. 1B). On the other hand, we did not observe any alterations in COX-1 protein levels after adding the same doses of NE along with LPS (Fig. 1A).

Next, we investigated whether our findings on the protein level were due to increased mRNA levels, using qualitative PCR. COX-2 mRNA was marginally detectable in unstimulated microglial cells. In contrast to the finding that NE alone did not influence COX-2 protein levels, a potent induction of COX-2 mRNA expression was observed after 2 h stimulation with NE alone, which resulted in a dose-response upregulation starting with 1 nM that peaked at 10 μM NE (Fig. 1C). Addition of LPS, 10 ng/ml, further enhanced the expression of COX-2 mRNA (Fig. 1D). Thus, in agreement with the effects observed on COX-2 protein levels, we found an increase in COX-2 mRNA when microglial cells were stimulated by both LPS plus NE.

Next we studied time kinetics in COX-2 mRNA and protein synthesis after stimulation with 10 ng/ml LPS or 1 μM NE and the combination of both. At 2 h, a slight increase in COX-2 immunoreactivity was detected when microglia were treated with LPS plus NE, while there was no change in COX-2 protein levels when the cells were treated with LPS or NE alone (Fig. 2A). LPS plus NE further increased COX-2 immunoreactivity significantly at 4 and 8 h compared to LPS treatment alone (p < 0.05). After 24 h, LPS alone reached the same immunoreactivity as the treatment of LPS plus NE (Fig. 2A and 2B).

COX-2 mRNA upregulation was already observed at 30 min upon LPS plus NE treatment and reached its maximum by 1 h. In LPS-only treated microglial cells COX-2 mRNA expression levels reached a maximum and the same expression level as LPS plus NE after 6 h. In LPS only and LPS plus NE, COX-2 level did not further increase and stayed at the same level after 24 h. Interestingly, NE alone also led to an increase in COX-2 mRNA expression by 30 min and was still observed after 8 h (Fig. 2C).

**NE increases release of PGE2 by LPS-stimulated primary microglial cells**

We further investigated whether the augmentation of COX-2 synthesis by NE in the presence of LPS is accompanied by an increased release of PGE₂, an important product of the enzymatic activity of COX-2 (Fig. 3). PGE₂ was barely detectable in unstimulated primary neonatal microglial cells. Treatment with NE, 1 μM alone, did not lead to an increase in PGE₂ over 24 h. LPS, 10 ng/ml alone, significantly increased PGE₂ concentration after 24 h (p < 0.05), whereas there was no significant increase after 4 and 8 h stimulation with LPS. We observed a significant increase in the secretion of PGE₂ after 8 h of stimulation with the combination of LPS (10 ng/ml) and NE (1 μM) compared to unstimulated cells (p < 0.05). At 24 h, LPS plus NE also showed a significant elevation of PGE₂ levels compared to treatment with LPS alone (p < 0.001). The enhancement of PGE₂ induced by NE in LPS-stimulated microglia, but not by NE alone, confirms the previous results in which NE in combination with LPS further increased COX-2 immunoreactivity whereas NE alone did not increase COX-2 protein levels.
The NE-induced increase in COX-2 is mediated by β-adrenoceptors

Since microglial cells express α- and β-adrenoceptors, and NE activates G-protein-coupled receptors, we asked which adrenoceptor subtype mediates the increase in COX-2 after stimulation with LPS in combination with NE. Thus, we treated microglial cells with LPS, 10 ng/ml, in combination with various adrenoreceptor agonists (Fig. 4A). Co-treatment of LPS with the selective α₁-adrenergic agonist phenylephrine only induced a modest increase in COX-2 protein expression compared to LPS and NE treatment, while clonidine, an α₂-adrenergic agonist, did not show any effect at all. In contrast, terbutaline and dobutamine, β₂- and unselective β-adrenergic agonists, respectively, mimicked the effect of NE (Fig. 4A). Thus, stimulation of microglial β₁- or β₂-receptors, or both, seem to be required for the observed effect on COX-2 protein levels, suggesting that treatment with β-adrenergic antagonists should abolish the enhanced COX-2 protein synthesis. Indeed, the selective β₁- and β₂-receptor antagonists CGP 20712A and ICI 118,551, respectively, reduced COX-2 protein levels induced by the combination of LPS/NE (Fig. 4B). However, they were not able to completely abolish COX-2 immunoreactivity (Fig. 4B). Nicergoline, an α₁/α₂-adrenoreceptor antagonist, had no effect on COX-2 protein levels induced by NE/ LPS, further supporting the absence of role of α₁/α₂- adrenoceptors.

Finally, we treated LPS-stimulated microglial cells with both β-adrenergic receptor agonists and antagonists (Fig. 4C). As shown, ICI 118,551 and CGP 20712A reduced COX-2 expression in LPS- plus dobutamine-stimulated cells. After stimulation with the β₂-selective agonist terbutaline plus LPS, addition of the β₁-receptor antagonist...
CGP completely abolished COX-2 expression. Low concentrations of ICI 118,551, however, did not alter COX-2 expression levels, while at higher concentrations a modest decrease was observed.

Discussion

In the present study, basal COX-2 expression in non-stimulated rat primary neonatal microglia was not detectable, suggesting that either COX-2 is generated by de novo synthesis in response to applied stimuli or, alternatively, that basal levels do not reach the threshold of immunoblot detection. NE alone induced COX-2 mRNA expression but did not affect COX-2 protein synthesis. We suppose that the COX-2 mRNA induced by NE is degraded before protein synthesis is initiated. Alternatively, a second stimulus, such as LPS, is required to set off translation of COX-2.

Different kinases are important in the regulation of COX-2 in LPS-stimulated microglia [37], and it has been demonstrated that NE increases the activity of mitogen-activated protein kinases (MAPK) [38] as well as transcription factors [39]. Kan et al. (1999) demonstrated that, in neonatal rat cardiac myocytes, NE alone increases the activity of MAPK and, although IL-1β alone does not induce the same effect, the co-addition of IL-1β and NE results in an enhanced MAPK activity in comparison to the substances alone [38]. Salmeterol and isoproterenol, β2- and non-selective β-adrenergic receptor agonists, respectively, enhance the phosphorylation of p38 MAPK and extracellular signal-regulated kinases (ERK) in peritoneal macrophages and RAW264.7 [40,41]. Interestingly, pretreatment with isoproterenol decreases the release of TNFα, IL-12 and NO in LPS-stimulated macrophages. On the contrary,
isoproterenol reduces the release of these same mediators after PMA stimulation, indicating that the effect of isoproterenol might depend on the stimulus [42].

Recently, Morioka et al. (2009) demonstrated that, in rat spinal microglia, NE reduces phosphorylation of p38 MAPK, induced by ATP, via β1- and β2-receptors [43]. The deactivation of p38 would lead to a decrease in COX-2 protein synthesis, since p38 is involved in COX-2 mRNA stabilization [44]. As such, it is possible that the observed increase in COX-2 mRNA may be due to increased transcription or increased stability of mRNA in rat microglia by activation of certain transcription factors and/or kinases. That could explain the increase in the COX-2 mRNA with incubation of cells with NE alone, or the enhancement of COX-2 protein synthesis when associated with LPS.

On the other hand, many post-transcriptional factors contribute to the translation of mRNA, which might not be affected by NE. This could explain the lack of effect of NE on COX-2 protein synthesis. For example, it is known that LPS induces the activation of the mammalian target of rapamycin (mTOR) [45]. Activation of mTOR induces translation of different mRNA through its downstream targets such as the ribosomal p70S6 kinase and the initiation factor 4E-binding protein 1 [46]. Although we did not test this possibility, it seems feasible that NE per se cannot activate the machinery responsible for the translation of COX-2 in rat microglia, but potentiates protein synthesis by increasing transcription or protein stability.

As shown before, LPS, 10 ng/ml, increases COX-2 mRNA and protein expression at 4 and 8 h, respectively [8]. Co-stimulation with NE already at low concentrations results in earlier and a markedly enhanced induction of COX-2 mRNA and protein levels. Similar to our results, other groups have also shown that NE per se does not increase protein synthesis, but drastically increases the effect induced by LPS. In peripheral blood monocytes and monocyte-derived macrophages, NE and epinephrine alone only show a minor effect on matrix metalloproteinase (MMP)-1 and MMP-9 production [39]. However, a combination of the catecholamine with LPS further enhances the increased production of MMP-1 and MMP-9.

Next, we investigated whether the increased intracellular levels of COX-2 evoked by LPS plus NE causes elevated levels of PGE2. In our experiments, NE plus LPS further increased the levels of PGE2. Interestingly, after 24 h stimulation with NE plus LPS, COX-2 mRNA and protein levels are similar to the increase observed in LPS alone. However, the increase observed in PGE2 is about three-fold higher in LPS plus NE than with LPS alone. Thus, it is possible that the combination of LPS and NE might induce the expression or increase the activity of other enzymes involved in PGE2 synthesis, such as phospholipase A2 and/or PGE synthases.

Dependent on the experimental setting, PGE2 can exert either neuroprotective or neurodetrimental effects. Agents reducing PGE2 synthesis in in vitro and in vivo
### Figure 4

**Effect of different α- and β-adrenergic agonists and antagonists on COX-2 protein expression.**

Microglial cells were stimulated with LPS 10 ng/ml and different adrenergic agonists/antagonists for 4 hours, followed by western blot analysis for COX-2 protein expression (70 kDa). (A) LPS-stimulated microglial cells were treated with different α- and β-adrenoreceptor agonists at two different concentrations (1 and 10 μM): α₁-agonist phenylephrine; α₂-agonist clonidine; β₁/β₂-agonist dobutamine; β₂-agonist terbutaline. (B) LPS-stimulated microglial cells were treated with different α- and β-adrenoreceptor antagonists at two different concentrations (1 and 10 μM): α₁/α₂-antagonist nicergoline; β₁-antagonist CGP 20712A; β₂-antagonist ICI118,551. (C) LPS-stimulated microglial cells were treated both with dobutamine or terbutaline and with the two different β-adrenoreceptor antagonists ICI 118,551 or CGP 20712A. [NE = norepinephrine].

**Table A**

|                  | LPS 10 ng/ml | NE 1 μM | Phenylephrine μM | Clonidine μM | Dobutamine μM | Terbutaline μM |
|------------------|--------------|---------|------------------|--------------|---------------|----------------|
|                  | - + + + + + + + + + | - - 1 10 | - - - - - - - - | - - - - - - | - - - - - 1 10 | - - - - - - 1 10 |

**Table B**

|                  | LPS 10 ng/ml | NE 1 μM | Nicergoline μM | CGP 20712A μM | ICI 118,551 μM |
|------------------|--------------|---------|----------------|----------------|----------------|
|                  | - + + + + + + + + | - - + + + + + + + | - - - - 1 10 | - - - - - 1 10 | - - - - - 1 10 |

**Table C**

|                  | LPS 10 ng/ml | Dobutamine 1 μM | Terbutaline 1 μM | CGP 20712A μM | ICI 118,551 μM |
|------------------|--------------|-----------------|------------------|----------------|----------------|
|                  | - + + + + + + + + | - + + + + + + + | - - - - - - - | - - - - - + + + + + | - - - - - 1 10 |

**Legend:**

- COX-2 (70kDa)

**Notes:**

- NE = norepinephrine
- LPS = lipopolysaccharide
- α = α-adrenergic
- β = β-adrenergic
models of chronic neurodegenerative diseases like Parkinson’s disease or AD have been demonstrated to be neuroprotective due to their anti-inflammatory effects [47-52]. On the other hand, exogenous PGE2 protects neurons from LPS-induced cell death by reduction of NO and reactive oxygen species [53]. Direct administration of PGE2 into the brain has also been shown to reduce microglial activation and TNF-α expression in brain parenchyma induced by intraperitoneal LPS injection [54]. In addition, PGE2 protects neurons in culture from different types of noxious stimuli [29,55,56].

Localized inflammatory responses in the brain parenchyma have been associated with the pathogenesis and progression of AD. Inhibition of neuroinflammation has been identified as a potential therapeautic target [57-60]. COX-2 expression is elevated in the AD brains [14,18] and PGE2 is accumulated in the cerebrospinal fluid of AD patients [61]. It was therefore reasonable to hypothesize that inhibition of COX-2 may have a therapeautic potential in AD. Despite convincing evidence in epidemiological studies on the prevention of AD through long-term treatment with non-steroidal anti-inflammatory drugs, most clinical trials have failed to show beneficial effects [62-65], suggesting that either the molecular target or the therapeutic window has been missed.

PGE2 acts on four different receptors, EP1-EP4 [66], of which microglia express three, namely EP1, EP2, and EP3; the latter having been exclusively detected in activated microglia [67]. Microglial EP2 receptors are known to enhance neurotoxic activities [10,50-52,68]. This would suggest that enhanced secretion of PGE2 through NE might increase microglial toxicity. However, the role of PGE2 may be far more complex due to the presence of other receptor subtypes on microglia. So far, NE-mediated regulation of EP receptor expression on microglia has not been studied.

In this study, we could show that the observed effect of NE is mediated by β-adrenoreceptor agonists. This corresponds to the findings of Minghetti and Levi, who showed that the non-selective β-adrenergic agonist isoproterenol increases COX-2 protein and PGE2 synthesis in microglial cells [8]. In our experiments, both β1- and β2-receptors seem to mediate the enhanced effect of COX-2 production. Our data also indicate a lack of involvement of α-adrenoreceptors. The use of relatively-selective β-adrenoreceptor antagonists allowed us to further confirm the participation of β-adrenoreceptors in the enhancement of LPS-induced COX-2 expression. Based on our data, both β-adrenoreceptor subtypes seem to be involved. The antagonists used in this study, CGP20712A (β1-antagonist) and ICI118,551 (β2-antagonist) are widely used to discern the role of β-adrenoreceptor subtypes [69,70]. Terbutaline is considered a relatively selective β2-agonist, but it also binds to the β1-adrenoreceptor [71]. As with any pharmacological agent, these compounds are not 100% selective, therefore future studies utilizing knockout animals will be needed to fully clarify the role of distinct β-adrenoreceptor subtypes.

We did not detect that stimulation of α-adrenoreceptors results in any significant increase in COX-2 protein levels. Of note, stimulation of β-adrenoreceptors increases levels of cAMP in microglial cells, mainly through activation of the β2-adrenoreceptor [25]. Raised intracellular cAMP levels are known to suppress activation of microglial cells [54,72,73]. Increased PGE2 levels may in addition stimulate the microglial EP2 receptor, which is linked to cAMP formation [74] and thereby contribute to the inactivation of microglia. Other cell culture experiments have shown that exogenous PGE2 results in decreased levels of pro-inflammatory cytokines such as TNF-alpha and IL-12 in LPS-stimulated microglia [75-77]. In concordance with these results, increased cAMP levels via stimulation of β-adrenoreceptors inhibits the production of macrophage inflammatory protein (MIP)-1a, which is known to activate macrophages to secrete pro-inflammatory cytokines [78].

Our data suggest that NE has a strong effect on microglial inflammatory responses, suggesting that NE is an active modulator of microglial activation. This may be important in AD, a disease in which early loss of noradrenergic locus coeruleus (LC) neurons has been observed [79]. Depletion of LC neurons by injection of the neurotoxin DSP4 increases the levels of inflammatory mediators like iNOS, IL-1β and IL-6 [80].

Conclusions
Our study shows that NE increases LPS-induced COX-2 expression and PGE2 secretion by primary rat neonatal microglia in vitro. These results shed new light on the role of NE in CNS inflammation. NE via COX-2 and PGE-2 induction may have a protective physiological function rather than being purely detrimental. However, further investigations in in vivo models, especially in regard to PGE2 and COX-2, may help to clarify the exact role of NE in neuroinflammation.

Acknowledgements
We thank Ulrike Götzinger-Berger and Brigitte Günter for excellent technical assistance. Antonio Carlos Pinheiro de Oliveira was supported by CAPES (Brasilia/Brazil). This work was supported by KNDD (Kompetenznetz Degenerative Demenzen).

Author details
1Department of Psychiatry and Psychotherapy, University Hospital of Freiburg, Freiburg, Germany. 2Division of Molecular Neurology, University of Erlangen, Erlangen, Germany. 3Department of Neurology, University of New Mexico, Albuquerque, NM, USA. 4Department of Neurology, Clinical Neurosciences, University of Bonn Medical Center, Bonn, Germany.
Authors’ contributions

JCM5 contributed to the design of the study, carried out western blot analysis, performed the statistical analysis and wrote the manuscript; BLF directed the work of the study, reviewed the data and the manuscript; EH participated in western blot analysis and prostaglandin measurements; ECI and ACPO provided consultation and reviewed the manuscript; MTH was involved in drafting the manuscript and revised it critically; MH conceived of the study, directed the work and reviewed the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 25 October 2009
Accepted: 11 January 2010 Published: 11 January 2010

References

1. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillant brain parenchyma in vivo. Science 2005, 308:1514-1518.

2. Davalos D, Gutierrez J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005, 8:752-759.

3. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394.

4. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.

5. Wright SD, Ramos RA, Tobais PS, Ulejchik RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1435.

6. Fassbender K, Walter S, Kuhl S, Lendmann R, Ishi K, Bertsch T, Stalder AK, Muehlauser F, Liu Y, Riebe K, Hertting G, Otomo M, Iadecola C. Prostaglandin E2 secretion by cultured human adult microglia: implications for Alzheimer’s disease. Brain Res 2002, 931:218-226.

7. Kavano T, Ando J, Mizumura K, Hanaguchi T, Hanisch UK. The role of cyclooxygenase and 2 arachidonic acid activation in prostaglandin E2 secretion by cultured human adult microglia: implications for Alzheimer’s disease. Brain Res 2002, 931:218-226.

8. Kavano T, Mizumura K, Hanaguchi T, Hanisch UK. The role of cyclooxygenase E2 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia: implications for Alzheimer’s disease. Brain Res 2002, 951:218-226.

9. Kavano T, Mizumura K, Hanaguchi T, Hanisch UK. The role of cyclooxygenase E2 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia: implications for Alzheimer’s disease. Brain Res 2002, 951:218-226.

10. Kavano T, Mizumura K, Hanaguchi T, Hanisch UK. The role of cyclooxygenase E2 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia: implications for Alzheimer’s disease. Brain Res 2002, 951:218-226.

11. Kavano T, Mizumura K, Hanaguchi T, Hanisch UK. The role of cyclooxygenase E2 and 2 activity in prostaglandin E2 secretion by cultured human adult microglia: implications for Alzheimer’s disease. Brain Res 2002, 951:218-226.
40. Magoci M, Vizi ES, Selimcic Z, Brozik A, Szelényi J. Multiple G-protein-coupling specificity of beta-adrenoceptor in macrophages. Immunology 2007, 122:503-513.

41. Tan KS, Nackley AG, Satterfield K, Maixner W, Diatchenko L, Flood PM. Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. Cell Signal 2007, 19:251-260.

42. Szelényi J, Selimcic Z, Brozik A, Medgyesi D, Magoci M. Dual beta-adrenergic modulation in the immune system: stimulus-dependent effect of isoproterenol on MAPK activation and inflammatory mediator production in macrophages. Neurochem Int 2006, 49:94-103.

43. Morolli N, Tanabe H, Inoue A, Dohi T, Nakata Y. Noradrenaline reduces the ATP-stimulated phosphorylation of p38 MAP kinase via beta-adrenergic receptors-CAMP-protein kinase A-dependent mechanism in cultured rat spinal microglia. Neurochem Int 2009, 55:226-234.

44. Ridley SH, Dean J, Satterfield SJ, Brook M, Clark AR, Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett 1998, 439:75-80.

45. Weichhart T, Costantino G, Pogliatsch M, Rosner M, Zeyda M, Stuhlmeyer KM, Kolbe T, Stulnig TM, Hörler H, Hengstschlager M, Müller M, Säemann MD. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008, 29:565-577.

46. Hay N, Servenborg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.

47. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Huang S. Role of cyclooxygenase-2 in interleukin-1beta-induced microglial activation. J Neurochem 2000, 75:5709-5714.

48. Scalici C, Prospero C, Venugucchi MG, Prepe G, Casamenti F. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer’s disease. Eur J Neurosci 2000, 12:1900-1912.

49. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunter S, Vila M, Jackson-Olson JN. Prostanoid receptors: structures, mechanisms. Adv Exp Med Biol 2003, 55:433-448.

50. Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, Wilson B, Reece JM, Thomas KD. Effects of rofecoxib on beta-adrenergic receptors-cAMP-protein kinase A-dependent mechanism in macrophages. J Pharmacol Exp Ther 2005, 315:157-165.

51. Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, Iadecola C. The role of COX-1 and COX-2 in Alzheimer disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurolex Disord 2005, 4:307-315.

52. Montine TJ, Wolter JL, Pan C, Montine KS, Zhang J. Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer’s disease. NeuroRx 2006, 3:336-343.

53. Martin BK, Szekely C, Brandt J, Pantziaros S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008, 65:896-905.

54. Reines SA, Block GA, Morris JC, Li G, Nessly ML, Lines CR, Norman BA, Baranac CC, Reines SA. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropharmacology 2005, 50:1204-1215.

55. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.

56. Craft JM, Watterson DM, Van Eldik LJ. Role of inflammation in neurodegenerative diseases. Neurology 2003, 61:1243-1253.

57. Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Prostanoid receptors: structures, mechanisms. Adv Exp Med Biol 2003, 55:79-88.

58. Hoozemans JJ, O'Donnell K, Askanazi J, Eikelenboom P. Prostaglandin E receptor subtypes in cultured rat spinal microglia. Neurochem Int 2004, 45:237-243.

59. Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ. Prostaglandin E2 receptor subtypes in cultured rat microglia. J Neurochem 2004, 90:1923-1934.

60. Minghetti L. Inflammatory drugs. Inflammation in neurodegenerative diseases. Curr Top Med Chem 2005, 5:707-716.

61. Montine TJ, Wolter JL, Pan C, Montine KS, Zhang J. Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer’s disease. NeuroRx 2006, 3:336-343.

62. Martin BK, Szekely C, Brandt J, Pantziaros S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008, 65:896-905.

63. Reines SA, Block GA, Morris JC, Li G, Nessly ML, Lines CR, Norman BA, Baranac CC, Reines SA. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropharmacology 2005, 50:1204-1215.

64. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.

65. Reines SA, Block GA, Morris JC, Li G, Nessly ML, Lines CR, Norman BA, Baranac CC. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 2004, 62:66-71.

66. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005, 144:317-322.

67. Slavik H, Voik B, Fiebich B, Hull M. Microglial expression of prostaglandin EP3 receptor in excitotoxic lesions in the rat stratum. Neurochem Int 2004, 45:653-660.

68. Sie C, Montine KS, Breyer RW, Montine TJ. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 2005, 52:70-77.

69. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005, 144:317-322.

70. Hoozemans JJ, O'Donnell K, Askanazi J, Eikelenboom P. Prostanoid receptors: structures, mechanisms. Adv Exp Med Biol 2003, 55:79-88.

71. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005, 144:317-322.

72. Hoozemans JJ, O’Donnell K, Askanazi J, Eikelenboom P. Prostanoid receptors: structures, mechanisms. Adv Exp Med Biol 2003, 55:79-88.

73. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005, 144:317-322.

74. Hoozemans JJ, O’Donnell K, Askanazi J, Eikelenboom P. Prostanoid receptors: structures, mechanisms. Adv Exp Med Biol 2003, 55:79-88.

75. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 2005, 144:317-322.

76. Hoozemans JJ, O’Donnell K, Askanazi J, Eikelenboom P. Prostanoid receptors: structures, mechanisms. Adv Exp Med Biol 2003, 55:79-88.